Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million

Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year